Antibacterial antisense oligonucleotide and method

Details Antibacterial antisense oligonucleotide and method Antibacterial antisense oligonucleotide and method

2007-05-11

2011-11-29

McGarry, Sean (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S006110, C435S375000, C536S023100, C536S024100, C514S04400A

Reexamination Certificate

active

08067571

ABSTRACT:
A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3′ or 5′ end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.

REFERENCES:
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5142047 (1992-08-01), Summerton et al.
patent: 5166315 (1992-11-01), Summerton et al.
patent: 5185444 (1993-02-01), Summerton et al.
patent: 5217866 (1993-06-01), Summerton et al.
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5521063 (1996-05-01), Summerton et al.
patent: 5580767 (1996-12-01), Cowsert et al.
patent: 5698685 (1997-12-01), Summerton et al.
patent: 5892023 (1999-04-01), Pirotzky et al.
patent: 6060456 (2000-05-01), Arnold et al.
patent: 6133246 (2000-10-01), McKay et al.
patent: 6228579 (2001-05-01), Zyskind et al.
patent: 6239265 (2001-05-01), Cook
patent: 6365351 (2002-04-01), Iversen
patent: 6495663 (2002-12-01), Rothbard
patent: 6548651 (2003-04-01), Nielsen et al.
patent: 6677153 (2004-01-01), Iversen
patent: 6828105 (2004-12-01), Stein et al.
patent: 6841542 (2005-01-01), Bartelmez et al.
patent: 7049431 (2006-05-01), Iversen et al.
patent: 7094765 (2006-08-01), Iversen et al.
patent: 7625873 (2009-12-01), Geller et al.
patent: 7943762 (2011-05-01), Weller et al.
patent: 2003/0224353 (2003-12-01), Stein et al.
patent: 2004/0110296 (2004-06-01), Vargeese et al.
patent: 2006/0148747 (2006-07-01), Stein et al.
patent: 2006/0281701 (2006-12-01), Stein et al.
patent: 2007/0021362 (2007-01-01), Geller et al.
patent: 2007/0135333 (2007-06-01), Geller et al.
patent: 2008/0194463 (2008-08-01), Weller et al.
patent: 9301286 (1993-01-01), None
patent: 9740854 (1997-11-01), None
patent: 0149775 (2001-07-01), None
patent: 02079467 (2002-10-01), None
patent: 02094250 (2002-11-01), None
patent: WO2004/097017 (2004-11-01), None
patent: 2006047683 (2006-05-01), None
patent: WO2006/050414 (2006-05-01), None
patent: 2006085973 (2006-08-01), None
patent: WO2007/009094 (2007-01-01), None
Agrawal et al., “Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides” Proc. Natl. Acad. Sci. USA 87(4): 1401-1405, 1990.
Agrawal et al., “Antisense therapeutics: is it as simple as complementary base recognition?” Molecular Med. Today 6: 72-81, 2000.
Agrawal, “Antinsense oligonucleotides: towards clinical trials” Tibtech 14(10): 376-387, 1996.
Branch, “A good antisense molecule is hard to find” Trends in Biochem. Sci. 23: 45-50, 1998.
Crooke, Antisense Research and Applications, ed. Springer, 1999, Chapter 1, “Basic Principles of Antisense Therapeutics” pp. 1-50.
Deere et al., “Antisense Phosphorodiamidate Morpholino Oligomer Length and Target Position Effects on Gene-Specific Inhibition inEscherichia coli” Antimicrobial Agents and Chemotherapy 49(1): 249-255, 2005.
Dryselius et al., “The Translation Start Codon Region Is Sensitive to Antisense PNA Inhibition inEscherichia coli” Oligonucleotides 13: 427-433, 2003.
Galloway et al., “A Mutant ofEscherichia coliDefective in the First Step of Endotoxin Biosynthesis” J. Biol. Chem. 265 (11): 6394-6402, 1990.
Geller et al., “Antisense Antibacterial Method and Compound” U.S. Appl. No. 12/613,428, filed Nov. 5, 2009.
Geller et al., “Antisense Antibacterial Method and Compound” U.S. Appl. No. 12/723,035, filed Mar. 12, 2010.
Good et al., “Antisense PNA effects inEscherichia coliare limited by the outer-membrane LPS layer” Microbiology 146 (Pt 10): 2665-2670, 2000.
Green et al., “Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease” J. Am. Coll. Surg. 191(1): 93-105, 2000.
Greenberg et al., “Antisense Phosphorodiamidate Morpholino Oligomers Targeted to an Essential Gene Inhibit Burkholderia cepacia Complex” The Journal of Infectious Diseases 201(12): 000-000, 2010.
International Search Report, mailed Aug. 11, 2006, for PCT/US2005/023553, 6 pages.
Jackowski et al., “Ratio of Active to Inactive Forms of Acyl Carrier Protein inEscherichia coli” J. Biol. Chem. 258(24): 15186-15191, 1983.
Jen et al., “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies” Stem Cells 18: 307-319, 2000.
Mellbye et al., “Variations in Amino Acid Composition of Antisense Peptide-Phosphorodiamidate Morpholino Oligomer Affect Potency againstEscherichia coliIn Vitro and In Vivo” Antimicrobial Agents and Chemotherapy 53(2): 525-530, 2009.
Micklefield, “Backbone Modification of Nucleic Acids: Synthesis, Structure and Therapeutic Applications” Curr. Med. Chem. 8(10): 1157-1179, 2001.
Mitev et al., “Inhibition of Intracellular Growth ofSalmonella entericaSerovar Typhimurium in Tissue Culture by Antisense Peptide-Phosphorodiamidate Morpholino Oligomer” Antimicrobial Agents and Chemotherapy 53(9): 3700-3704, 2009.
Moulton et al., “Cellular Uptake of Antisense Morpholino Oligomers Conjugated to Arginine-Rich Peptides” Bioconjugate Chem. 15: 290-299, 2004.
Moulton et al., “HIV Tat Peptide Enhances Cellular Delivery of Antisense Morpholino Oligomers” Antisense & Nucleic Acid Drug Dev. 13: 31-43, 2003.
Moulton et al., “Peptide-assisted delivery of steric-blocking antisense oligomers” Curr. Opin. Mol. Ther. 5(2): 123-132, 2003.
Nelson et al., “Arginine-Rich Peptide Conjugation to Morpholino Oligomers: Effects on Antisense Activity and Specificity” Bioconjugate Chem. 16: 959-966, 2005.
Nielsen, “Peptide nucleic acids as antibacterial agents via the antisense principle” Exp. Opin. Invest. Drugs 10(2): 331-341, 2001.
Nielsen, “Peptide nucleic acids: on the road to new gene therapeutic drugs” Pharmacol. Toxicol. 86(1): 3-7, 2000.
Partridge et al., “A Simple Method for Delivering Morpholino Antisense Oligos into the Cytoplasm of Cells” Antisense & Nucleic Acid Drug Dev. 6(3): 169-175, 1996.
Petersen et al., “Synthesis of Thymidine Dimers Containing Piperazine in the Internucleoside Linkage and their Incorporation into Oligodeoxynucleotides” Tetrahedron 51(7): 2145-2154, 1995.
Polacco et al., “A Mutant ofEscherichia coliConditionally Defective in the Synthesis of Holo-[Acyl Carrier Protein]” J. Biol. Chem. 256(11): 5750-5754, 1981.
Rothbard et al., “Arginine-Rich Molecular Transporters for Drug Delivery: Role of Backbone Spacing in Cellular Uptake” J. Med. Chem. 45: 3612-3618, 2002.
Stein et al., “A Specificity Comparison of Four Antisense Types: Morpholino, 2′-O-Methyl RNA, DNA, and Phosphorothioate DNA” Antisense & Nucleic Acid Drug Development 7(3): 151-157, 1997.
Summerton, “Morpholino antisense oligomers: the case for an RNase H-independent structural type” Biochim. et. Biophys. ACTA 1489(1): 141-157, 1999.
Summerton, Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules, Landes Bioscience/Eurekah.com and Kluwer Academic/Plenum Publishers, ed. C.G. Janson and M.J. During, 2006, Chapter 6, “Morpholinos and PNAs Compared” pp. 97-101.
Uhlmann et al., “Antisense Oligonucleotides: A New Therapeutic Principle” Chemical Reviews 90(4): 544-584, 1990.
Wang et al., “Assessment of the utilization of the antisense RNA strategy to identify essential genes in heterologous bacteria” FEMS Microbiology Letters 220(2): 171-176, 2003.
Weller et al., “Antibacterial Antisense Oligonucleotide and Method” U.S. Appl. No. 12/723,

Affiliated with

Also associated with

Rating

Antibacterial antisense oligonucleotide and method does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibacterial antisense oligonucleotide and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibacterial antisense oligonucleotide and method will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4293426